Analyse
Hotez and his team at Texas Children’s Hospital/Baylor College of Medicine created **Corbevax**, a protein subunit vaccine designed to be affordable (targeting ~$1.50/dose) and patent-free for global use. While geopolitical tensions (e.g., U.S.-China rivalry, vaccine nationalism) *did* hinder equitable distribution, other barriers played significant roles: **delayed WHO EUL approval** (granted only in **Dec 2022**), limited manufacturing partnerships outside India (where it was primarily produced by Biological E.), and skepticism from countries already committed to mRNA or viral-vector vaccines. The claim oversimplifies the systemic challenges but correctly highlights geopolitics as *one* major obstacle.
Achtergrond
Corbevax was authorized for emergency use in **India (Dec 2021)** and later in **Indonesia, Botswana, and others**, but its rollout lagged behind Pfizer/Moderna/AstraZeneca. Hotez repeatedly criticized global inequities, arguing that intellectual property waivers (e.g., **TRIPS waiver debates at WTO**) and production monopolies by Western pharma delayed alternatives like Corbevax. The vaccine’s traditional technology (similar to hepatitis B vaccines) made it easier to produce but less attractive to wealthier nations prioritizing newer platforms.
Samenvatting verdict
Peter Hotez’s team did develop a low-cost, patent-free COVID-19 vaccine (Corbevax), but its global adoption was limited by factors beyond *just* geopolitics, including regulatory hurdles, production scalability, and competition from established vaccines.